Insmed Inc

INSM

Company Profile

  • Business description

    Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

  • Contact

    700 US Highway 202/206
    BridgewaterNJ08807
    USA

    T: +1 908 977-9900

    E: [email protected]

    https://www.insmed.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    1,664

Stocks News & Analysis

stocks

Cheap e-commerce share continues sales momentum

The e-commerce business continues its sales momentum despite challenging backdrop.
stocks

Chart of the Week: Booming mined commodity prices see little value on offer

Iran War disruptions drive thermal coal and aluminum prices higher but value to be found in other pockets.
stocks

3 ASX top picks to combat inflation

The mechanics behind inflation resilient ASX businesses.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,886.401.700.02%
CAC 408,207.8934.780.43%
DAX 4025,177.807.09-0.03%
Dow JONES (US)50,644.28182.600.36%
FTSE 10010,505.0113.620.13%
HKSE24,959.87368.36-1.45%
NASDAQ26,674.7318.550.07%
Nikkei 22565,108.61109.200.17%
NZX 50 Index13,255.0527.240.21%
S&P 5007,520.361.240.02%
S&P/ASX 2008,659.104.600.05%
SSE Composite Index4,076.4717.26-0.42%

Market Movers